Over 20 years ago, the synaptic protein α-synuclein was identified as the primary component
of the Lewy bodies (LBs) that are a sine qua non of Parkinson's disease (PD). Since that …

Central nervous system (CNS) barriers predominantly mediate the immune-privileged status
of the brain, and are also important regulators of neuroimmune communication. It is …

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and
neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and …

The neurovascular unit (NVU) regulates metabolic homeostasis as well as drug
pharmacokinetics and pharmacodynamics in the central nervous system. Metabolic fluxes …

A common feature of many neurodegenerative diseases is the deposition of β-sheet-rich
amyloid aggregates formed by proteins specific to these diseases. These protein aggregates …

Over the last three decades, monoclonal antibodies have made a dramatic transformation
from scientific tools to powerful human therapeutics. At present, approximately 30 …

Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide.
Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and …

The main receptors for amyloid-beta peptide (Aβ) transport across the blood-brain barrier
(BBB) from brain to blood and blood to brain are low-density lipoprotein receptor related …

Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused
ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier …

Immunotherapy for Alzheimer's disease (AD) relies on antibodies directed against toxic
amyloid-beta peptide (Aβ), which circulate in the bloodstream and remove Aβ from the …